A Phase I Study of FCN-411 in Advanced Non-small Cell Lung Cancer Chinese Patients With EGFR Positive Mutation
Status:
Recruiting
Trial end date:
2021-12-20
Target enrollment:
Participant gender:
Summary
This phase I trial with dose-escalation stage and dose-expansion stage is the first-in-human
study of FCN-411, a drug being developed for treatment of advanced cancers. The initial
purpose of the study is to determine the maximum tolerated dose (MTD) and the recommended
phase 2 dose (RP2D) of FCN-411 monotherapy in EGFR-positive mutation non-small cell lung
cancer chinese patients. The study will also provide early information on how the body
handles the drug (pharmacokinetics) and on the anti-tumor activities of FCN-411.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Ahon Pharmaceutical Co., Ltd.
Collaborator:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences